Timothy Heffernan

List of Publications by Year
in descending order

30 papers	4,608 citations	304743 22 h-index	454955 30 g-index
31 all docs	31 docs citations	31 times ranked	9565 citing authors

#	Article	IF	Citations
1	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature, 2022, 606, 797-803.	27.8	54
2	BI-3406, a Potent and Selective SOS1â€“KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Cancer Discovery, 2021, 11, 142-157.	9.4	223
3	Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. Cancer Discovery, 2021, 11, 2094-2111.	9.4	66
4	Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Cancer Research, 2021, 81, 4054-4065.	0.9	24
5	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nature Communications, 2021, 12, 4626.	12.8	31
6	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology, 2021, 161, 196-210.	1.3	23
7	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science, 2021, 373, eabj0486.	12.6	99
8	Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 5572-5581.	0.9	75
9	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf -mutated melanoma. OncoImmunology, 2021, 10, 1992880.	4.6	7
10	Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nature Communications, 2021, 12, 6340.	12.8	17
11	EGFRAmplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clinical Cancer Research, 2020, 26, 1395-1407.	7.0	26
12	Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R. Journal of Medicinal Chemistry, 2020, 63, 9888-9911.	6.4	14
13	Pharmacologic profiling of patient-derived xenograft models of primary treatment-naÃ¯ve triple-negative breast cancer. Scientific Reports, 2020, 10, 17899.	3.3	9
14	Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. Journal of Medicinal Chemistry, 2020, 63, 12957-12977.	6.4	48
15	Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib. Cancer Research, 2020, 80, 4840-4853.	0.9	49
16	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell, 2020, 37, 720-734.e13.	16.8	74
17	Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. Cancers, 2019, 11, 1321.	3.7	34
18	Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Science Translational Medicine, 2019, 11, .	12.4	161

#	Article	IF	Citations
19	Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Science Translational Medicine, 2019, 11, .	12.4	192
20	Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. Cancers, 2019, 11, 462.	3.7	20
21	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature, 2019, 568, 410-414.	27.8	129
22	ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Science Translational Medicine, 2019, 11, .	12.4	42
23	High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nature Communications, 2018, 9, 5079.	12.8	91
24	An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nature Medicine, 2018, 24, 1036-1046.	30.7	622
25	In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype. Cancer Discovery, 2016, 6, 650-663.	9.4	59
26	Efficacy of the combination of MEK and CDK4/6 inhibitorsin vitroandin vivoin KRAS mutant colorectal cancer models. Oncotarget, 2016, 7, 39595-39608.	1.8	101
27	Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 2015, 5, 860-877.	9.4	696
28	Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. Cancer Research, 2015, 75, 1091-1101.	0.9	68
29	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature, 2014, 514, 628-632.	27.8	998
30	Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. Cell, 2014, 158, 185-197.	28.9	553